Cascade Investment Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Cascade Investment Group's BMY Position: Q1 2026 in Review
Cascade Investment Group reduced its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, selling an estimated $35K and leaving 4,965 shares worth $301K. The position accounts for 0.2% of the portfolio, ranked #116.
Cascade Investment Group first reported a position in BMY in Q4 2022 and has held it in 9 quarters since. The position peaked at $348K in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Cascade Investment Group held 4,965 shares of Bristol-Myers Squibb worth $301K as of Q1 2026.
- Cascade Investment Group sold 600 Bristol-Myers Squibb shares in Q1 2026, an estimated $35K.
- Bristol-Myers Squibb made up 0.2% of Cascade Investment Group's portfolio in Q1 2026, its #116 holding.
- Cascade Investment Group first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 9 quarters since.
- Cascade Investment Group's Bristol-Myers Squibb position peaked at $348K in Q1 2025.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Cascade Investment Group's 13F filing for Q1 2026, filed 13 May 2026.